A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution as Adjunctive Therapy With Vigabatrin as Initial Therapy in Patients With Infantile Spasms

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution as Adjunctive Therapy With Vigabatrin as Initial Therapy in Patients With Infantile Spasms

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 May 2018

At a glance

  • Drugs Cannabidiol (Primary) ; Vigabatrin
  • Indications Infantile spasms
  • Focus Registrational; Therapeutic Use
  • Sponsors INSYS Therapeutics, Inc
  • Most Recent Events

    • 02 Mar 2018 According to an INSYS Therapeutics media release, status changed from not yet recruiting to recruiting.
    • 01 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Mar 2018.
    • 07 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top